Work on reducing import dependence for raw materials: Commerce Secretary Rajesh Agrawal to pharma industry

The Indian pharma sector is strategically important, and government backing for self-reliance in raw materials can significantly de-risk supply chains and improve margins. This aligns with a broader 'Make in India' push, making the sector attractive for long-term investment.

Look for pharma companies with strong R&D, backward integration into APIs, and a growing export footprint; consider accumulating on dips with a medium to long-term horizon.

For Indian markets, this story mainly matters for SUNPHARMA, LUPIN, AUROPHARMA and the Pharmaceuticals, Chemicals pocket. The current signal is bullish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Major Indian pharma player, stands to benefit from reduced import dependence and increased domestic production focus. Prominent Indian pharmaceutical company, aligns with the government's vision for a stronger domestic pharma sector. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Commerce Secretary Rajesh Agrawal urged the Indian pharmaceutical sector to boost domestic production.
• •The call is to reduce reliance on imported raw materials.
• •Emphasis was placed on diversifying export markets to navigate global uncertainties.
• •Agrawal stressed the need for India to become a global hub for quality and cost-effective medicines.
• •The focus is on innovation and moving towards a value-driven industry.